Cellular therapies for type 1 diabetes.
Cellular therapies for type 1 diabetes.
复制标题
1 型糖尿病的细胞疗法。
DOI：
10.1055/s-2008-1042430
复制
发表时间：
2008
期刊：
影响因子：
--
通讯作者：
Chong,AS
中科院分区：
文献类型：
--
作者：
Lee,DD;Grossman,E;Chong,AS
1型糖尿病（T1DM）是一种由产生胰岛素的β细胞的选择性自身免疫破坏引起的疾病。由于胰岛素产生的单细胞性质，这种疾病过程适合于细胞治疗。小鼠模型为研究用于治疗糖尿病的细胞疗法提供了机会，包括胰岛移植的研究，以及干细胞疗法和胰岛再生的可能性。胰岛移植的研究包括同种异体和异种移植，并允许研究逆转自身免疫和实现免疫耐受的新方法。来自造血来源的干细胞，如骨髓和胎儿脐带血，以及来自胰腺、肠、肝和脾的干细胞，有望成为胰岛的新来源，或者可以作为胰岛再生的刺激物。本综述将总结各种细胞干预研究作为T1DM的潜在治疗。
Type 1 diabetes mellitus (T1DM) is a disease that results from the selective autoimmune destruction of insulin-producing β-cells. This disease process lends itself to cellular therapy because of the single cell nature of insulin production. Murine models have provided opportunities for the study of cellular therapies for the treatment of diabetes, including the investigation of islet transplantation, and also the possibility of stem cell therapies and islet regeneration. Studies in islet transplantation have included both allo-and xeno-transplantation and have allowed for the study of new approaches for the reversal of autoimmunity and achieving immune tolerance. Stem cells from hematopoietic sources such as bone marrow and fetal cord blood, as well as from the pancreas, intestine, liver, and spleen promise either new sources of islets or may function as stimulators of islet regeneration. This review will summarize the various cellular interventions investigated as potential treatments of T1DM.